Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METalmark
2023-508256-19-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of amivantamab and capmatinib in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Primary endpoints: Incidence and severity of adverse events including dose-limiting toxicities and Objective response rate. Planned start Dec 2023; status: authorised.
02
Drugs
amivantamabcapmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508256-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508256-19-00.